Li Jingxian, Zhou Bingjie, Wang Shiting, Ouyang Jiayi, Jiang Xinyi, Wang Chenglin, Zhou Teng, Zheng Ke-Wei, Wang Junqing, Wang Jiaqi
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China.
Shenzhen Qiyu Biotechnology Co., Ltd., Shenzhen 518107, China.
Bioengineering (Basel). 2024 Apr 15;11(4):381. doi: 10.3390/bioengineering11040381.
Nanobodies have emerged as promising tools in biomedicine due to their single-chain structure and inherent stability. They generally have convex paratopes, which potentially prefer different epitope sites in an antigen compared to traditional antibodies. In this study, a synthetic phage display nanobody library was constructed and used to identify nanobodies targeting a tumor-associated antigen, the human B7-H3 protein. Combining next-generation sequencing and single-clone validation, two nanobodies were identified to specifically bind B7-H3 with medium nanomolar affinities. Further characterization revealed that these two clones targeted a different epitope compared to known B7-H3-specific antibodies, which have been explored in clinical trials. Furthermore, one of the clones, dubbed as A6, exhibited potent antibody-dependent cell-mediated cytotoxicity (ADCC) against a colorectal cancer cell line with an EC50 of 0.67 nM, upon conversion to an Fc-enhanced IgG format. These findings underscore a cost-effective strategy that bypasses the lengthy immunization process, offering potential rapid access to nanobodies targeting unexplored antigenic sites.
由于其单链结构和固有的稳定性,纳米抗体已成为生物医学领域中很有前景的工具。它们通常具有凸形互补决定区,与传统抗体相比,可能更倾向于识别抗原中不同的表位位点。在本研究中,构建了一个合成噬菌体展示纳米抗体文库,并用于鉴定靶向肿瘤相关抗原——人B7-H3蛋白的纳米抗体。结合下一代测序和单克隆验证,鉴定出两种纳米抗体,它们以中等纳摩尔亲和力特异性结合B7-H3。进一步的表征显示,与已在临床试验中探索的已知B7-H3特异性抗体相比,这两个克隆靶向不同的表位。此外,其中一个克隆(命名为A6)在转化为Fc增强型IgG形式后,可以对结肠癌细胞系表现出强大的抗体依赖性细胞介导的细胞毒性(ADCC),其半数有效浓度(EC50)为0.67 nM。这些发现强调了一种具有成本效益的策略,该策略绕过了漫长的免疫过程,有可能快速获得靶向未探索抗原位点的纳米抗体。